Worldwide Healthcare (Ordinary Share) WWH

Sector Specialist: Biotechnology/Life Sciences

Register or Sign in to receive email alerts for items in your favourites whenever we write about them

Add to Virtual Portfolio | Print page

Estimated NAV

1722.00

Share Price

1580.64

Total Returns on £1000 over 

Fund / Benchmark Total returns(%)
Worldwide Healthcare (Ordinary Share) Price 80.26%
Worldwide Healthcare (Ordinary Share) NAV 82.91%
FTSE World 22.55%
Total Returns on £1000

Discount / Premium Movement

Discount / Premium Movement

Shares

Share Type Yesterday's
Closing Price
Discount / Premium Diluted NAV Gearing Dividend
Est Last
Ordinary Share 1604.0 -6.9% 1722.00 1746.00
05 Feb
114% 0.78%

Discrete performance % over

Fund / BenchmarkMar '13
Feb '14
Mar '14
Feb '15
Mar '15
Feb '16
Worldwide Healthcare (Ordinary Share) Price40.7343.08-10.48
Worldwide Healthcare (Ordinary Share) NAV38.8837.87-4.47
FTSE World11.2317.10-5.91

Discrete performance over

Discrete Performance

Top 10 Holdings

Bristol-Myers Squibb Company 5.49%
Allergan, Inc. 5.29%
HCA Holdings Inc 4.39%
Novartis AG 3.79%
AbbVie Inc 3.59%
ONO Pharmaceutical Co., Ltd. 3.49%
Amgen Inc 3.19%
Regeneron Pharmaceuticals, Inc. 2.89%
Biogen Idec Inc., 2.69%
Boston Scientific, Inc. 2.69%

Sectors weighting

Pharmaceuticals 100.20%
General Equity -0.10%
Net Current Assets -0.20%

Regional weighting

North America Region 57.00%
Europe Developed ex-UK 18.00%
Japan 9.00%
Asia exc Japan 7.00%
Other Countries 4.00%
Cash/Cash Equivalent 4.00%
Fixed Interest 2.00%
  • Investment trust info:

  • Sector Sector Specialist: Biotechnology/Life Sciences
  • Launch Date 28 Apr 1995
  • Currency GBX
  • Domicile UK
  • Share Price 1580.64
  • Share Type Ordinary Share
  • TIDM WWH
  • ISIN GB0003385308
  • Shares Issued (M) 48
  • Market Capital (£M) 766.55
  • Gross Assets (£M) 933.88
  • Net Assets (£M) 822.84
  • TER (%) 1.01
  • Historic Dividend Yield (%) 0.78
  • Last AGM 24 Sep 2015
  • Next AGM 24 Sep 2016
  • Last Annual Report Date 16 Jun 2014
  • Next due Report Date 31 Mar 2015
  • Next due Report Type A/R
  • Objective:

  • To invest worldwide in a diversified portfolio of shares in pharmaceutical and biotechnology companies and related securities in the healthcare sector.
  • Management Group(s):

  • Close Finsbury Asset Management Ltd
  • Frostrow Capital LLP
  • OrbiMed Capital LLC
  • OrbiMed Capital LLC
  • Managed by:

  • Samuel. D Isaly Start: 28 Apr 1995
  • Sven Borho Start: 01 Feb 2013
  • Management Contract & Fees:

    OrbiMed, the Investment Manager, receives a periodic fee equal to 0.65% p.a. of the Company's net asset value. The Investment Management Agreement may be terminated by either party giving notice of not less than 12 months. Frostrow, the Administrator, receives a periodic fee equal to 0.30% p.a. of the Company's market capitalisation up to £150m, 0.20% p.a. of the market capitalisation in excess of £ 150m and up to £500m, and 0.125% p.a. of the market capitalisation in excess of £500m, plus a fixed amount equal to £ 57,500 p.a.. Dependent on the level of long-term outperformance of the Company, the Investment Manager and the Administrator are entitled to the payment of a performance fee. The performance fee amounts to 16.5% of any outperformance of the NAV over the benchmark index, the Investment Manager receiving 15% and the Administrator receiving 1.5% respectively.